|
Sign In to gain access to subscriptions and/or personal tools.
|
Rationale and Design of the Pediatric Critical Illness Stress-Induced Immune Suppression Prevention Trial
Joseph Carcillo, MD1*,
Richard Holubkov, PhD2,
J. Michael Dean, MD2,
John Berger, MD3,
Kathleen L. Meert4,
K. J. S. Anand, MBBS, DPhil5,
Jerry Zimmerman, MD, PhD6,
Christopher J. L. Newth, MB, ChB7,
Rick Harrison, MD8,
Douglas F. Willson, MD9,
Carol Nicholson, MD10,
and
The Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network
1 Children's Hospital of Pittsburgh
2 University of Utah
3 Children's National Medical Center
4 Children's Hospital of Michigan
5 Arkansas Children's Hospital
6 Seattle Children's Hospital
7 Children's Hospital Los Angeles
8 University of California at Los Angeles
9 University of Virginia Children's Hospital
10 National Institute of Child Health and Human Development
* To whom correspondence should be addressed. E-mail: carcilloja{at}ccm.upmc.edu.
 |
Abstract |
|---|
Despite implementation of CDC recommendations and bundled interventions for preventing catheter-associated blood stream infection, ventilator-associated pneumonia, or urinary catheter–associated infections, nosocomial infections and sepsis remain a significant cause of morbidity and mortality in critically ill children. Recent studies suggest that acquired critical illness stress-induced immune suppression (CRISIS) plays a role in the development of nosocomial infection and sepsis. This condition can be related to inadequate zinc, selenium, and glutamine levels, as well as hypoprolactinemia, leading to stress-induced lymphopenia, a predominant TH2 monocyte/macrophage state, and subsequent immune suppression. Prolonged immune dysfunction increases the likelihood of nosocomial infections associated with invasive devices. Although strategies to prevent common complications of critical illness are routinely employed (eg, prophylaxis for gastrointestinal bleeding, thrombophlebitis), no prophylactic strategy is used to prevent stress-induced immune suppression. This is the authors rationale for the pediatric CRISIS prevention trial (NCT00395161), designed as a randomized, double-blind, controlled clinical investigation to determine if daily enteral supplementation with zinc, selenium, and glutamine as well as parenteral metoclopramide (a dopamine 2 receptor antagonist that reverses hypoprolactinemia) prolongs the time until onset of nosocomial infection or sepsis in critically ill children compared to enteral supplementation with whey protein. If effective, this combined nutritional and pharmacologic approach may lessen the excess morbidity and mortality as well as resource utilization associated with nosocomial infections and sepsis in this population. The authors present the design and analytic plan for the CRISIS prevention trial. (JPEN J Parenter Enteral Nutr. XXXX;xx:xx-xx)
First published on April 14, 2009, doi:10.1177/0148607108327392
Journal of Parenteral and Enteral Nutrition 2009;33:368.
A more recent version of this article appeared on July 1, 2009
This version was published on April
21, 2009

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
|
|